Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 32 entries
Sorted by: Best Match Show Resources per page
Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.

Oncotarget

Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K.
PMID: 29100358
Oncotarget. 2017 Aug 12;8(44):76921-76934. doi: 10.18632/oncotarget.20217. eCollection 2017 Sep 29.

Doxorubicin, a widely used chemotherapeutic drug, has several potential high-risk side effects including cardiomyopathy. Furthermore, cellular resistance to this drug develops with time. By using liposomes as carrier vesicles both the side effects and drug resistance might be avoided....

Cite
Øverbye A, Holsæter AM, Markus F, et al. Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. Oncotarget. 2017;8(44):76921-76934doi: 10.18632/oncotarget.20217.
Øverbye, A., Holsæter, A. M., Markus, F., Škalko-Basnet, N., Iversen, T. G., Torgersen, M. L., Sønstevold, T., Engebraaten, O., Flatmark, K., Mælandsmo, G. M., Skotland, T., & Sandvig, K. (2017). Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. Oncotarget, 8(44), 76921-76934. https://doi.org/10.18632/oncotarget.20217
Øverbye, Anders, et al. "Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide." Oncotarget vol. 8,44 (2017): 76921-76934. doi: https://doi.org/10.18632/oncotarget.20217
Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K. Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. Oncotarget. 2017 Aug 12;8(44):76921-76934. doi: 10.18632/oncotarget.20217. eCollection 2017 Sep 29. PMID: 29100358; PMCID: PMC5652752.
Copy Download .nbib Format: NLM
Metastases in locally advanced rectal cancer undergoing curatively intended treatment.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Mariathasan AB, Boye K, Dueland S, Flatmark K, Larsen SG.
PMID: 34049768
Eur J Surg Oncol. 2021 Sep;47(9):2377-2383. doi: 10.1016/j.ejso.2021.04.023. Epub 2021 Apr 27.

BACKGROUND: The main cause of mortality in locally advanced rectal cancer (LARC) is metastatic progression. The aim of the present study was to describe frequency, pattern and outcome of metastatic disease in a cohort of LARC patients after curative...

Cite
Mariathasan AB, Boye K, Dueland S, et al. Metastases in locally advanced rectal cancer undergoing curatively intended treatment. Eur J Surg Oncol. 2021;47(9):2377-2383doi: 10.1016/j.ejso.2021.04.023.
Mariathasan, A. B., Boye, K., Dueland, S., Flatmark, K., & Larsen, S. G. (2021). Metastases in locally advanced rectal cancer undergoing curatively intended treatment. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 47(9), 2377-2383. https://doi.org/10.1016/j.ejso.2021.04.023
Mariathasan, Anthony B, et al. "Metastases in locally advanced rectal cancer undergoing curatively intended treatment." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology vol. 47,9 (2021): 2377-2383. doi: https://doi.org/10.1016/j.ejso.2021.04.023
Mariathasan AB, Boye K, Dueland S, Flatmark K, Larsen SG. Metastases in locally advanced rectal cancer undergoing curatively intended treatment. Eur J Surg Oncol. 2021 Sep;47(9):2377-2383. doi: 10.1016/j.ejso.2021.04.023. Epub 2021 Apr 27. PMID: 34049768.
Copy Download .nbib Format: NLM
Peptide vaccine targeting mutated .

Journal for immunotherapy of cancer

Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM.
PMID: 34711663
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003109.

CONCLUSION: These findings point to the existence of a pre-existing immunity in patients with PMP towards mutated Gsα, which has been insufficient to control tumor growth, possibly because of inhibition of antitumor T cells by upregulation of immune checkpoint...

Cite
Flatmark K, Torgunrud A, Fleten KG, et al. Peptide vaccine targeting mutated . J Immunother Cancer. 2021;9(10)doi: 10.1136/jitc-2021-003109.
Flatmark, K., Torgunrud, A., Fleten, K. G., Davidson, B., Juul, H. V., Mensali, N., Lund-Andersen, C., & Inderberg, E. M. (2021). Peptide vaccine targeting mutated . Journal for immunotherapy of cancer, 9(10), . https://doi.org/10.1136/jitc-2021-003109
Flatmark, Kjersti, et al. "Peptide vaccine targeting mutated ." Journal for immunotherapy of cancer vol. 9,10 (2021). doi: https://doi.org/10.1136/jitc-2021-003109
Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM. Peptide vaccine targeting mutated . J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003109. PMID: 34711663; PMCID: PMC8557294.
Copy Download .nbib Format: NLM
Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review.

Journal of gastrointestinal oncology

Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K.
PMID: 33968437
J Gastrointest Oncol. 2021 Apr;12:S191-S203. doi: 10.21037/jgo-20-136.

High-throughput "-omics" analysis may provide a broader and deeper understanding of cancer biology to define prognostic and predictive biomarkers and identify novel therapy targets. In this review we provide an overview of studies where the peritoneal tumor component of...

Cite
Lund-Andersen C, Torgunrud A, Fleten KG, et al. Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review. J Gastrointest Oncol. 2021;12:S191-S203doi: 10.21037/jgo-20-136.
Lund-Andersen, C., Torgunrud, A., Fleten, K. G., & Flatmark, K. (2021). Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review. Journal of gastrointestinal oncology, 12S191-S203. https://doi.org/10.21037/jgo-20-136
Lund-Andersen, Christin, et al. "Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review." Journal of gastrointestinal oncology vol. 12 (2021): S191-S203. doi: https://doi.org/10.21037/jgo-20-136
Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K. Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review. J Gastrointest Oncol. 2021 Apr;12:S191-S203. doi: 10.21037/jgo-20-136. PMID: 33968437; PMCID: PMC8100703.
Copy Download .nbib Format: NLM
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.

Translational oncology

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM.
PMID: 31096111
Transl Oncol. 2019 Jul;12(7):951-958. doi: 10.1016/j.tranon.2019.04.001. Epub 2019 May 13.

Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay,...

Cite
Flørenes VA, Flem-Karlsen K, McFadden E, et al. A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Transl Oncol. 2019;12(7):951-958doi: 10.1016/j.tranon.2019.04.001.
Flørenes, V. A., Flem-Karlsen, K., McFadden, E., Bergheim, I. R., Nygaard, V., Nygård, V., Farstad, I. N., Øy, G. F., Emilsen, E., Giller-Fleten, K., Ree, A. H., Flatmark, K., Gullestad, H. P., Hermann, R., Ryder, T., Wernhoff, P., & Mælandsmo, G. M. (2019). A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Translational oncology, 12(7), 951-958. https://doi.org/10.1016/j.tranon.2019.04.001
Flørenes, Vivi Ann, et al. "A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases." Translational oncology vol. 12,7 (2019): 951-958. doi: https://doi.org/10.1016/j.tranon.2019.04.001
Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM. A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Transl Oncol. 2019 Jul;12(7):951-958. doi: 10.1016/j.tranon.2019.04.001. Epub 2019 May 13. PMID: 31096111; PMCID: PMC6520638.
Copy Download .nbib Format: NLM
Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?.

Clinical and translational radiation oncology

Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH.
PMID: 31872084
Clin Transl Radiat Oncol. 2019 Dec 02;21:5-10. doi: 10.1016/j.ctro.2019.11.006. eCollection 2020 Mar.

BACKGROUND AND PURPOSE: We investigated how features relating to pelvic cavity anatomy and tumor hemodynamic factors may influence systemic failure in rectal cancer.MATERIALS AND METHODS: Rectal cancer patients (207 women, 343 men), who had been prospectively enrolled onto six...

Cite
Meltzer S, Bakke KM, Rød KL, et al. Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?. Clin Transl Radiat Oncol. 2019;21:5-10doi: 10.1016/j.ctro.2019.11.006.
Meltzer, S., Bakke, K. M., Rød, K. L., Negård, A., Flatmark, K., Solbakken, A. M., Kristensen, A. T., Fuglestad, A. J., Kersten, C., Dueland, S., Seierstad, T., Hole, K. H., Lyckander, L. G., Larsen, F. O., Schou, J. V., Patrick Brown, D., Abrahamsson, H., Redalen, K. R., & Ree, A. H. (2020). Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?. Clinical and translational radiation oncology, 215-10. https://doi.org/10.1016/j.ctro.2019.11.006
Meltzer, Sebastian, et al. "Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?." Clinical and translational radiation oncology vol. 21 (2020): 5-10. doi: https://doi.org/10.1016/j.ctro.2019.11.006
Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH. Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?. Clin Transl Radiat Oncol. 2019 Dec 02;21:5-10. doi: 10.1016/j.ctro.2019.11.006. eCollection 2020 Mar. PMID: 31872084; PMCID: PMC6909215.
Copy Download .nbib Format: NLM
MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts.

Acta oncologica (Stockholm, Sweden)

Knuth F, Adde IA, Huynh BN, Groendahl AR, Winter RM, Negård A, Holmedal SH, Meltzer S, Ree AH, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Futsaether CM.
PMID: 34918621
Acta Oncol. 2021 Dec 17;1-9. doi: 10.1080/0284186X.2021.2013530. Epub 2021 Dec 17.

BACKGROUND: Tumor delineation is time- and labor-intensive and prone to inter- and intraobserver variations. Magnetic resonance imaging (MRI) provides good soft tissue contrast, and functional MRI captures tissue properties that may be valuable for tumor delineation. We explored MRI-based...

Cite
Knuth F, Adde IA, Huynh BN, et al. MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts. Acta Oncol. 2021;1-9doi: 10.1080/0284186X.2021.2013530.
Knuth, F., Adde, I. A., Huynh, B. N., Groendahl, A. R., Winter, R. M., Negård, A., Holmedal, S. H., Meltzer, S., Ree, A. H., Flatmark, K., Dueland, S., Hole, K. H., Seierstad, T., Redalen, K. R., & Futsaether, C. M. (2021). MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts. Acta oncologica (Stockholm, Sweden), 1-9. https://doi.org/10.1080/0284186X.2021.2013530
Knuth, Franziska, et al. "MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts." Acta oncologica (Stockholm, Sweden) vol. (2021): 1-9. doi: https://doi.org/10.1080/0284186X.2021.2013530
Knuth F, Adde IA, Huynh BN, Groendahl AR, Winter RM, Negård A, Holmedal SH, Meltzer S, Ree AH, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Futsaether CM. MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts. Acta Oncol. 2021 Dec 17;1-9. doi: 10.1080/0284186X.2021.2013530. Epub 2021 Dec 17. PMID: 34918621.
Copy Download .nbib Format: NLM
Comparison of reliability of magnetic resonance imaging using cartilage and T1-weighted sequences in the assessment of the closure of the growth plates at the knee.

Acta radiologica open

Kvist OF, Dallora AL, Nilsson O, Anderberg P, Berglund JS, Flodmark CE, Diaz S.
PMID: 33088592
Acta Radiol Open. 2020 Sep 30;9(9):2058460120962732. doi: 10.1177/2058460120962732. eCollection 2020 Sep.

BACKGROUND: Growth development is traditionally evaluated with plain radiographs of the hand and wrist to visualize bone structures using ionizing radiation. Meanwhile, MRI visualizes bone and cartilaginous tissue without radiation exposure.PURPOSE: To determine the state of growth plate closure...

Cite
Kvist OF, Dallora AL, Nilsson O, et al. Comparison of reliability of magnetic resonance imaging using cartilage and T1-weighted sequences in the assessment of the closure of the growth plates at the knee. Acta Radiol Open. 2020;9(9):2058460120962732doi: 10.1177/2058460120962732.
Kvist, O. F., Dallora, A. L., Nilsson, O., Anderberg, P., Berglund, J. S., Flodmark, C. E., & Diaz, S. (2020). Comparison of reliability of magnetic resonance imaging using cartilage and T1-weighted sequences in the assessment of the closure of the growth plates at the knee. Acta radiologica open, 9(9), 2058460120962732. https://doi.org/10.1177/2058460120962732
Kvist, Ola Ft, et al. "Comparison of reliability of magnetic resonance imaging using cartilage and T1-weighted sequences in the assessment of the closure of the growth plates at the knee." Acta radiologica open vol. 9,9 (2020): 2058460120962732. doi: https://doi.org/10.1177/2058460120962732
Kvist OF, Dallora AL, Nilsson O, Anderberg P, Berglund JS, Flodmark CE, Diaz S. Comparison of reliability of magnetic resonance imaging using cartilage and T1-weighted sequences in the assessment of the closure of the growth plates at the knee. Acta Radiol Open. 2020 Sep 30;9(9):2058460120962732. doi: 10.1177/2058460120962732. eCollection 2020 Sep. PMID: 33088592; PMCID: PMC7545521.
Copy Download .nbib Format: NLM
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

ESMO open

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K.
PMID: 28761742
ESMO Open. 2017 May 02;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017.

OBJECTIVE: Through the conduct of an individual-based intervention study, the main purpose of this project was to build and evaluate the required infrastructure that may enable routine practice of precision cancer medicine in the public health services of Norway,...

Cite
Ree AH, Russnes HG, Heinrich D, et al. Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open. 2017;2(2):e000158doi: 10.1136/esmoopen-2017-000158.
Ree, A. H., Russnes, H. G., Heinrich, D., Dueland, S., Boye, K., Nygaard, V., Silwal-Pandit, L., Østrup, O., Hovig, E., Nygaard, V., Rødland, E. A., Nakken, S., Øien, J. T., Johansen, C., Bergheim, I. R., Skarpeteig, V., Sathermugathevan, M., Sauer, T., Lund-Iversen, M., Beiske, K., Nasser, S., Julsrud, L., Reisse, C. H., Ruud, E. A., Flørenes, V. A., Hagene, K. T., Aas, E., Lurås, H., Johnsen-Soriano, S., Geitvik, G. A., Lingjærde, O. C., Børresen-Dale, A. L., Mælandsmo, G. M., & Flatmark, K. (2017). Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO open, 2(2), e000158. https://doi.org/10.1136/esmoopen-2017-000158
Ree, Anne Hansen, et al. "Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate." ESMO open vol. 2,2 (2017): e000158. doi: https://doi.org/10.1136/esmoopen-2017-000158
Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K. Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open. 2017 May 02;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017. PMID: 28761742; PMCID: PMC5519811.
Copy Download .nbib Format: NLM
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases.

Oncotarget

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K.
PMID: 29100312
Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29.

BACKGROUND: Metastatic colorectal cancer (CRC) is associated with highly variable clinical outcome and response to therapy. The recently identified consensus molecular subtypes (CMS1-4) have prognostic and therapeutic implications in primary CRC, but whether these subtypes are valid for metastatic...

Cite
Østrup O, Dagenborg VJ, Rødland EA, et al. Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. Oncotarget. 2017;8(44):76290-76304doi: 10.18632/oncotarget.19350.
Østrup, O., Dagenborg, V. J., Rødland, E. A., Skarpeteig, V., Silwal-Pandit, L., Grzyb, K., Berstad, A. E., Fretland, �. �. A., Mælandsmo, G. M., Børresen-Dale, A. L., Ree, A. H., Edwin, B., Nygaard, V., & Flatmark, K. (2017). Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. Oncotarget, 8(44), 76290-76304. https://doi.org/10.18632/oncotarget.19350
Østrup, Olga, et al. "Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases." Oncotarget vol. 8,44 (2017): 76290-76304. doi: https://doi.org/10.18632/oncotarget.19350
Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K. Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29. PMID: 29100312; PMCID: PMC5652706.
Copy Download .nbib Format: NLM
MirGeneDB 2.0: the metazoan microRNA complement.

Nucleic acids research

Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ.
PMID: 31642479
Nucleic Acids Res. 2020 Jan 08;48:D1172. doi: 10.1093/nar/gkz1016.

No abstract available.

Cite
Fromm B, Domanska D, Høye E, et al. MirGeneDB 2.0: the metazoan microRNA complement. Nucleic Acids Res. 2020;48:D1172doi: 10.1093/nar/gkz1016.
Fromm, B., Domanska, D., Høye, E., Ovchinnikov, V., Kang, W., Aparicio-Puerta, E., Johansen, M., Flatmark, K., Mathelier, A., Hovig, E., Hackenberg, M., Friedländer, M. R., & Peterson, K. J. (2020). MirGeneDB 2.0: the metazoan microRNA complement. Nucleic acids research, 48D1172. https://doi.org/10.1093/nar/gkz1016
Fromm, Bastian, et al. "MirGeneDB 2.0: the metazoan microRNA complement." Nucleic acids research vol. 48 (2020): D1172. doi: https://doi.org/10.1093/nar/gkz1016
Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ. MirGeneDB 2.0: the metazoan microRNA complement. Nucleic Acids Res. 2020 Jan 08;48:D1172. doi: 10.1093/nar/gkz1016. PMID: 31642479; PMCID: PMC7145716.
Copy Download .nbib Format: NLM
Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer.

Translational oncology

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH.
PMID: 30273860
Transl Oncol. 2019 Jan;12(1):76-83. doi: 10.1016/j.tranon.2018.09.010. Epub 2018 Sep 29.

Tumor hypoxia contributes to therapy resistance and metastatic progression of locally advanced rectal cancer (LARC). We postulated that the tumor mitochondrial metabolism, manifested by reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) damage, reflects how hypoxic conditions connect to...

Cite
Bousquet PA, Meltzer S, Sønstevold L, et al. Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer. Transl Oncol. 2018;12(1):76-83doi: 10.1016/j.tranon.2018.09.010.
Bousquet, P. A., Meltzer, S., Sønstevold, L., Esbensen, Y., Dueland, S., Flatmark, K., Sitter, B., Bathen, T. F., Seierstad, T., Redalen, K. R., Eide, L., & Ree, A. H. (2019). Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer. Translational oncology, 12(1), 76-83. https://doi.org/10.1016/j.tranon.2018.09.010
Bousquet, Paula A, et al. "Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer." Translational oncology vol. 12,1 (2019): 76-83. doi: https://doi.org/10.1016/j.tranon.2018.09.010
Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH. Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer. Transl Oncol. 2019 Jan;12(1):76-83. doi: 10.1016/j.tranon.2018.09.010. Epub 2018 Sep 29. PMID: 30273860; PMCID: PMC6170256.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 32 entries